Skip to main content
top-banner

Haleon announces fully paid 26-week equal parental leave for all employees globally

LONDON, 18 JULY 2022: Haleon plc, a global leader in consumer health, today announces the launch of a market leading parental leave policy to coincide with its first day as an independent company. All employees globally will be entitled to 26-weeks fully paid parental leave following the arrival of a child into their lives. The policy is open to all employees, regardless of gender or sexuality and covers biological birth, surrogacy and adoption.

This policy is one of the most progressive among multinational companies globally and reflects Haleon’s intent to take a leading position as an employer of choice in the exciting growth sector of consumer health. It is a commitment to give equal opportunities to everyone, regardless of gender, to focus on raising a family, in the knowledge that their Haleon careers can continue to flourish. Announced on Haleon’s first day of trading following its demerger from GSK, it sets the tone for our plans to foster an inclusive environment, a key pillar of our broader Diversity, Equity & Inclusion strategy.

Mairéad Nayager, Chief HR Officer, said: “Haleon has a compelling purpose to deliver better everyday health with humanity, and what better way to live this purpose than to support colleagues at an important time in their lives. This is a market leading parental leave policy and is central to Haleon’s ambition of creating an inclusive and diverse workforce and supporting our colleagues to thrive both within their family environment and at work. I am so proud that we can announce this policy on the birth date of Haleon!”

The new parental leave policy is effective from 1 January 2023.

ENDS

Media Relations

Nidaa Lone +44 (0)7841400607 nidaa.g.lone@haleon.com
Louise Pyman +44 (0)7586495121 louise.x.pyman@haleon.com

About Haleon

Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. The group employs over 22,000 people across 170 markets, who are united by Haleon’s purpose - to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com